AbbVie invests $650 million in a dual-targeting immunotherapy from RemeGen, enhancing its oncology portfolio.
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
Lilly Ventyx acquisition for $1.2B focuses on NLRP3 inflammasome drugs, expanding Lilly’s immune drug pipeline.
Amgen acquires Dark Blue for up to $840M, gaining a protein-degrading drug targeting acute myeloid leukemia.
BioMarin Amicus acquisition for $4.8B adds a late-stage asset and two marketed therapies generating $450M in nine months.
BioMarin Amicus acquisition valued at $4.8 billion adds a late-stage asset and two marketed therapies generating $450 million.
Xoma acquires Generation Bio, a gene therapy developer, in a strategic move to enhance its biotech portfolio.
Pfizer obesity pill China deal involves a $2 billion agreement with Fosun Pharma, aiming to enhance its weight loss medication offerings.
Mirum Bluejay acquisition secures a late-stage hepatitis D drug, enhancing its pipeline with potential $200M in additional payouts.
Contingent value rights are increasingly used in biotech deals, bridging price gaps amid market turbulence.
Contingent value rights are increasingly used in biotech deals to bridge price gaps amid market turbulence.#PharmaSignal #Biotech #MergersAndAcquisitions